Table 1 Baseline clinical characteristics of patients with different chemo-mobilization regimens (n = 128)
Variables | Cyclophosphamide (n = 65) | Etoposide (n = 63) | P-value |
|---|---|---|---|
Median age, year (range) | 55.0 (39 ~ 64) | 57.0 (34 ~ 65) | 0.359 |
Male, n (%) | 39 (60.0%) | 36 (57.1%) | 0.743 |
Ig type, n (%) | 0.173 | ||
IgG | 35 (53.8%) | 44 (69.8%) | |
IgA | 8 (12.3%) | 6 (9.5%) | |
IgM | 1 (1.5%) | 1 (1.6%) | |
Light chain only | 21 (32.3%) | 11 (17.5%) | |
ISS, n (%) | 0.356 | ||
I | 22 (33.8%) | 15 (23.8%) | |
II | 21 (32.3%) | 27 (42.9%) | |
III | 22 (33.8%) | 21 (33.3%) | |
ECOG PS ≥ 2, n (%) | 6 (9.2%) | 2 (3.2%) | 0.274 |
LDH > (1 × ULN), n (%) | 7 (10.9%) | 11 (17.5%) | 0.292 |
Median BM plasma cells, %, range | 35.0 (4.0 ~ 90.0) | 27.0 (0.9 ~ 95.8) | 0.068 |
Median lymphocyte count, (× 109/L), range | 2.00 (0.4 ~ 6.23) | 2.19 (0.57 ~ 4.78) | 0.340 |
Serum creatinine ≥2 mg/dL, n (%) | 13 (20.3%) | 8 (12.7%) | 0.340 |
Median platelet count (× 109/L), range | 201 (48 ~ 393) | 206 (63 ~ 509) | 0.802 |
Median serum Hb, g/dL | 9.8 (4.9 ~ 15.3) | 10.0 (6.2 ~ 15.4) | 0.577 |
Median time to mobilization, months (range) | 4.67 (2.53 ~ 6.80) | 3.88 (2.43 ~ 6.18) | < 0.001 |
Frontline treatment, n (%) | |||
Thalidomide-based | 59 (81.9%) | 20 (31.3%) | |
Bortezomib-based | 7 (9.7%) | 14 (21.9%) | |
Bortezomib+Thalidomide | 0 (0.0%) | 29 (45.3%) | |
Conventional chemotherapy | 6 (8.3%) | 1 (1.6%) | |
Median prior treatment cycle, n, range | 4 (3 ~ 7) | 4 (3 ~ 6) | 0.056 |
Radiotherapy (spine), n (%) | 18 (27.7%) | 15 (23.8%) | 0.616 |
Disease status at mobilization | 0.359 | ||
CR | 12 (18.5%) | 16 (25.4%) | |
VGPR | 14 (21.5%) | 7 (11.1%) | |
PR | 36 (55.4%) | 38 (60.3%) | |
SD | 3 (4.6%) | 2 (3.2%) | |
PD | 0 (0.0%) | 0 (0.0%) | |